Ventas, Inc. VTR
We take great care to ensure that the data presented and summarized in this overview for Ventas, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VTR
View all-
Vanguard Group Inc Valley Forge, PA68.9MShares$4.33 Billion0.09% of portfolio
-
Black Rock Inc. New York, NY43.3MShares$2.72 Billion0.05% of portfolio
-
Jpmorgan Chase & CO New York, NY32.3MShares$2.03 Billion0.17% of portfolio
-
State Street Corp Boston, MA26.6MShares$1.67 Billion0.08% of portfolio
-
Principal Financial Group Inc Des Moines, IA16.5MShares$1.03 Billion0.68% of portfolio
-
Geode Capital Management, LLC Boston, MA11.7MShares$731 Million0.06% of portfolio
-
Apg Asset Management Us Inc. New York, NY11.6MShares$730 Million6.24% of portfolio
-
Resolution Capital LTD Sydney, Nsw, C37.89MShares$495 Million10.64% of portfolio
-
Centersquare Investment Management LLC Plymouth Meeting, PA6.84MShares$429 Million5.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.41MShares$403 Million0.05% of portfolio
Latest Institutional Activity in VTR
Top Purchases
Top Sells
About VTR
Ventas, an S&P 500 company, operates at the intersection of two powerful and dynamic industries ? healthcare and real estate. As one of the world's foremost Real Estate Investment Trusts (REIT), we use the power of capital to unlock the value of real estate, partnering with leading care providers, developers, research and medical institutions, innovators and healthcare organizations whose success is buoyed by the demographic tailwind of an aging population. For more than twenty years, Ventas has followed a successful strategy that endures: combining a high-quality diversified portfolio of properties and capital sources to manage through cycles, working with industry leading partners, and a collaborative and experienced team focused on producing consistent growing cash flows and superior returns on a strong balance sheet, ultimately rewarding Ventas shareholders. As of September 30, 2020, Ventas owned or managed through unconsolidated joint ventures approximately 1,200 properties.
Insider Transactions at VTR
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jul 01
2025
|
Matthew J Lustig Director |
BUY
Grant, award, or other acquisition
|
Direct |
516
+0.57%
|
$31,992
$62.87 P/Share
|
Jul 01
2025
|
Roxanne M Martino Director |
BUY
Grant, award, or other acquisition
|
Direct |
846
+1.36%
|
$52,452
$62.87 P/Share
|
Jul 01
2025
|
Sumit Roy Director |
BUY
Grant, award, or other acquisition
|
Direct |
497
+2.35%
|
$30,814
$62.87 P/Share
|
Jul 01
2025
|
Maurice S Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
596
+2.19%
|
$36,952
$62.87 P/Share
|
May 30
2025
|
Carey S. Roberts EVP and GC |
SELL
Open market or private sale
|
Direct |
23,500
-16.77%
|
$1,504,000
$64.23 P/Share
|
May 27
2025
|
Robert F Probst EVP and CFO |
SELL
Open market or private sale
|
Direct |
17,374
-9.35%
|
$1,129,310
$65.22 P/Share
|
May 27
2025
|
Robert F Probst EVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,374
+8.55%
|
$1,077,188
$62.22 P/Share
|
May 21
2025
|
Robert F Probst EVP and CFO |
SELL
Open market or private sale
|
Direct |
69,592
-17.12%
|
$4,453,888
$64.6 P/Share
|
May 21
2025
|
Robert F Probst EVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
33,592
+14.26%
|
$1,780,376
$53.79 P/Share
|
May 14
2025
|
Walter C Rakowich Director |
SELL
Open market or private sale
|
Direct |
1,459
-5.05%
|
$91,917
$63.76 P/Share
|
May 13
2025
|
Melody C Barnes Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,882
+8.04%
|
$184,448
$64.18 P/Share
|
May 13
2025
|
Theodore Bigman Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,882
+25.12%
|
$184,448
$64.18 P/Share
|
May 13
2025
|
Michael J Embler Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,882
+16.71%
|
$184,448
$64.18 P/Share
|
May 13
2025
|
Matthew J Lustig Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,882
+3.11%
|
$184,448
$64.18 P/Share
|
May 13
2025
|
Roxanne M Martino Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,882
+4.55%
|
$184,448
$64.18 P/Share
|
May 13
2025
|
Marguerite M Nader Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,882
+12.0%
|
$184,448
$64.18 P/Share
|
May 13
2025
|
Sean P. Nolan Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,882
+10.67%
|
$184,448
$64.18 P/Share
|
May 13
2025
|
Walter C Rakowich Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,882
+9.06%
|
$184,448
$64.18 P/Share
|
May 13
2025
|
Joe Vasquez Rodriguez Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,882
+27.31%
|
$184,448
$64.18 P/Share
|
May 13
2025
|
Sumit Roy Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,882
+12.52%
|
$184,448
$64.18 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 579K shares |
---|---|
Exercise of conversion of derivative security | 737K shares |
Payment of exercise price or tax liability | 213K shares |
---|---|
Bona fide gift | 10K shares |
Open market or private sale | 840K shares |